Article Text

PDF
Eplerenone treatment alleviates the development of joint lesions in a new rat model of spontaneous metabolic-associated osteoarthritis
  1. Chaohua Deng1,2,
  2. Arnaud Bianchi1,2,
  3. Nathalie Presle1,2,
  4. David Moulin1,2,3,
  5. Meriem Koufany1,2,
  6. Cécile Guillaume1,
  7. Anne Pizard2,3,4,5,
  8. Hervé Kempf1,2
  1. 1UMR7365 CNRS-Université de Lorraine, IMoPA, Ingénierie Moléculaire et Physiopathologie Articulaire, Vandoeuvre-les-Nancy, France
  2. 2Fédération de Recherche 3209, Vandoeuvre-les-Nancy, France
  3. 3CHRU Nancy, Vandoeuvre-les-Nancy, France
  4. 4UMRS-Inserm U1116, Université de Lorraine, Vandoeuvre-les-Nancy, France
  5. 5CIC-P1433 Inserm, CHRU Nancy, Vandoeuvre-les-Nancy, France
  1. Correspondence to Dr Anne Pizard, UMRS-Inserm U1116, CHRU Nancy, ILCV, 4 rue du Morvan, Vandoeuvre-les-Nancy 54500, France; anne.pizard{at}inserm.fr and Dr Hervé Kempf, UMR 7365 CNRS-UL, IMoPA, 9 avenue de la Forêt de Haye, Vandoeuvre-lès-Nancy 54500, France; herve.kempf{at}inserm.fr

Statistics from Altmetric.com

Increasing epidemiological and clinical studies suggest that metabolic syndrome (MetS) plays a role in the incidence and progression of osteoarthritis (OA).1 2 However, in absence of an appropriate MetS-associated OA experimental model,3 the MetS contribution to the joint phenotype in OA remains difficult to investigate and the evaluation of potential disease-modifying OA drugs (DMOADs) is complicated. Noteworthy, in contrast to their lean SHHF+/+(spontaneously hypertensive heart failure) controls, obese SHHFcp/cp rats, a well-characterised model of MetS,4 develop drastic metabolic, cardiovascular and renal alterations that are substantially improved through an early chronic mineralocorticoid receptor antagonism (MRA) treatment.5 Thus, by comparing young (1.5 months) and aged (12.5 months) lean SHHF+/+ and obese SHHFcp/cp rats, we sought to evaluate for the first time the potential (1) contribution of MetS to joint alterations and (2) therapeutic benefits derived from chronic MRA treatment by eplerenone (figure 1A).

Figure 1

Preventive 11-month treatment with mineralocorticoid receptor antagonist eplerenone alleviated the metabolic syndrome (MetS)-associated joint lesions in SHHF model. (A) Experimental design of the study. Lean spontaneously hypertensive heart failure (SHHF+/+) and obese SHHFcp/cp rats were divided randomly into treatment groups. Untreated groups (n=4 …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.